5-Jun-2026
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Citius Oncology (CTOR)
TipRanks (Wed, 3-Jun 12:50 PM ET)
BioLife Highlights Strategy Shift in New Investor Presentation
TipRanks (Wed, 3-Jun 8:34 AM ET)
BioLife Solutions Reports First Quarter 2026 Financial Results
PRNewswire (Thu, 7-May 4:03 PM ET)
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
PRNewswire (Thu, 23-Apr 4:03 PM ET)
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal CryoCase
PRNewswire (Tue, 21-Apr 4:15 PM ET)
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Biolife Solutions trades on the NASDAQ stock market under the symbol BLFS.
As of June 5, 2026, BLFS stock price declined to $26.65 with 680,772 million shares trading.
BLFS has a beta of 1.50, meaning it tends to be more sensitive to market movements. BLFS has a correlation of 0.17 to the broad based SPY ETF.
BLFS has a market cap of $1.30 billion. This is considered a Small Cap stock.
Last quarter Biolife Solutions reported $28 million in Revenue and $.04 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.
In the last 3 years, BLFS traded as high as $29.62 and as low as $8.92.
The top ETF exchange traded funds that BLFS belongs to (by Net Assets): IJR, VTI, IWM, SPSM, IWO.
BLFS has underperformed the market in the last year with a return of +24.0%, while SPY returned +25.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BLFS shares. However, BLFS has outperformed the market in the last 3 month and 2 week periods, returning +32.5% and +11.3%, while SPY returned +8.5% and -1.1%, respectively. This indicates BLFS has been having a stronger performance recently.
BLFS support price is $26.07 and resistance is $28.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BLFS shares will trade within this expected range on the day.